Cagrilintide vs Enclomiphene
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
CagrilintideGLP-1 / Weight Loss Agonists
Enclomiphene- Summary
- Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
- Enclomiphene is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that stimulates endogenous testosterone production by blocking estrogen negative feedback on the hypothalamus and pituitary. Unlike TRT, it restores testosterone while preserving or increasing sperm production and testicular volume.
- Half-Life
- ~7–10 days
- 5-7 days (long half-life; accumulates)
- Admin Route
- SubQ
- Oral
- Research
- —
- —
- Typical Dose
- 0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
- 12.5-25 mg per day
- Frequency
- Once weekly
- Once daily or every other day
- Key Benefits
- ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
- Synergistic appetite suppression complementing GLP-1 receptor agonists
- Reduces post-meal glucagon excursions improving glycemic control
- Slows gastric emptying contributing to prolonged satiety
- Once-weekly dosing via subcutaneous injection
- Potential for greater weight loss than semaglutide monotherapy
- Restores testosterone to normal range without exogenous androgen administration
- Preserves or increases sperm production and fertility
- Maintains testicular volume (unlike TRT which causes testicular atrophy)
- LH and FSH levels rise, indicating intact HPG axis function
- Option for hypogonadal men desiring fertility
- Oral administration (no injection required)
- Side Effects
- Nausea (most common, especially during titration)
- Vomiting
- Decreased appetite
- Diarrhea
- +2 more
- Visual disturbances (rare but class-related SERM effect)
- Mood changes or irritability
- Hot flashes
- Elevated estradiol in some users
- +2 more
- Stacks With
- —
- —